Gastroenteritis Clinical Trial
— CURIOSITYOfficial title:
Observational, Prospective Study to Evaluate Biomarkers as Indicators of Bacterial or Viral Infection During Acute Infectious Diseases
Verified date | March 2016 |
Source | MeMed Diagnostics Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Observational |
This is an observational prospective study of an in-vitro diagnostic (IVD) assay planned to
enroll 632 subjects. The study will be conducted in two stages: Stage A is aimed at
identifying individual biomarkers and constructing a multi-parametric diagnostic model,
whereas Stage B is aimed at testing the multi-parametric diagnostic model using a fresh
cohort of patients.
A collection of clinical, radiological and laboratory data will be gathered in order to
establish a final diagnosis. Blood samples will be analyzed and the levels of approximately
700 and 250,000 biomarkers will be determined using immunoassays and molecular measurements
respectively.
A final diagnosis will be determined based on a majority decision of a panel of three or
more independent physicians. Based on the final diagnosis, the accuracy of individual
biomarkers and combined sets of biomarkers for differentiating between distinct groups of
patients will be evaluated.
Status | Completed |
Enrollment | 1001 |
Est. completion date | September 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 1 Month and older |
Eligibility |
Inclusion Criteria: Patients who are at least one month old and are willing (either the subject or his legal guardian) to sign an informed consent will be eligible for inclusion. For the infectious and non-infectious disease groups, additional inclusion criteria have to be met. These will include: In the Infectious disease group: - Peak fever >37.5°C (99.5°F) - Clinical suspicion of an acute infectious disease - Symptoms duration = 12 days In the Non-infectious disease control group: - A non-infectious disease or healthy individuals Exclusion Criteria: Patients who will meet one or more of the following criteria will be excluded from the study: - Evidence of another episode of acute infectious disease in the last two weeks - Diagnosed congenital immune deficiency (CID) - Current treatment with immunosuppressive therapy such as: Active chemotherapy,Post-transplant drugs,High dose steroids (>1 mg/kg/day prednisone or equivalent). - Active radiotherapy - Immune-modulating/suppressive drugs including monoclonal antibodies, intravenous immunoglobulin (IVIG), cyclosporine, and anti-TNF agents - Current treatment with immune stimulants such as: Interleukin (IL)-2, Granulocyte-Monocytes/Granulocyte colony-stimulating factor (GM/G-CSF),Interferon. - An active hematological malignancy - A diagnosis of myelodysplastic syndrome or myeloproliferative disease - A proven or suspected human immunodeficiency virus (HIV)-1, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Israel | Hillel Yaffe Hospital | Hadera | |
Israel | Bnei Zion Hospital | Haifa |
Lead Sponsor | Collaborator |
---|---|
MeMed Diagnostics Ltd. |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The sensitivity and specificity of a multi-parametric diagnostic assay in differentiating between bacterial and viral etiology in patients with an acute infectious disease | We will evaluate the sensitivity and specificity of a multi-parametric diagnostic model, incorporating up to five different blood bio-markers in differentiating between bacterial and viral etiology in patients with an acute infectious disease. | 0-10 days after the initiation of symptoms | No |
Secondary | The sensitivity and specificity of individual biomarkers in differentiating between bacterial and viral etiology in patients with an acute infectious disease | We will evaluate the sensitivity and specificity of individual bio-markers in differentiating between bacterial and viral etiology in patients with an acute infectious disease. | 0-10 days after the initiation of symptoms | No |
Secondary | The sensitivity and specificity of a multi-parametric assay in differentiating between mixed (bacterial and viral co-infection) and pure viral infections in patients with an acute infectious disease | We will evaluate the sensitivity and specificity of a multi-parametric diagnostic assay incorporating up to five different blood bio-markers, in differentiating between mixed infection(bacterial and viral co-infection) and pure viral infection in patients with an acute infectious disease. | 0-10 days after the initiation of symptoms | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01168401 -
Bivalent Norovirus Vaccine Study
|
Phase 1 | |
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT02473887 -
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
|
Phase 1 | |
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Not yet recruiting |
NCT01671137 -
Probiotic for the Prevention of Functional Disorders in Childhood
|
N/A | |
Withdrawn |
NCT00691275 -
Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
|
N/A | |
Recruiting |
NCT06025695 -
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
|
Phase 3 | |
Completed |
NCT04463082 -
Non-invasive Assessment of the Current State of Hydration in Children by Ultrasound
|
N/A | |
Completed |
NCT02497417 -
A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients
|
N/A | |
Active, not recruiting |
NCT03000296 -
Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease
|
N/A | |
Completed |
NCT01236066 -
Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia
|
N/A | |
Completed |
NCT01225042 -
The Effect of Probiotics on E. Coli Gastroenteritis
|
N/A | |
Recruiting |
NCT00987519 -
Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age
|
N/A | |
Terminated |
NCT01357174 -
ROTATEQ™ Post-Marketing Surveillance in the Philippines
|
N/A | |
Completed |
NCT01033799 -
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
|
N/A | |
Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
Terminated |
NCT02568189 -
Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration
|
N/A | |
Terminated |
NCT02165813 -
Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children
|
Phase 2/Phase 3 | |
Completed |
NCT01853124 -
Emergency Department Probiotic Treatment of Pediatric Gastroenteritis
|
Phase 3 |